Recently, news that ‘a drug costing over 30,000 RMB per dose was allegedly administered to a child despite suspected loss of efficacy’ has sparked widespread public concern. According to reports, a hospital used this high-cost, specialized medication—priced at more than 30,000 RMB per vial—in treating a child with a rare disease. However, the drug may have been compromised during transportation or storage due to improper temperature control. Despite uncertainty about its effectiveness, the hospital reportedly administered it without confirmation of potency. The incident has raised serious questions about quality oversight of expensive medications, clinical protocols in healthcare institutions, and patients’ right to informed consent.Experts emphasize that such high-value biologics are often extremely sensitive to storage conditions; even minor deviations from required temperature or humidity ranges can significantly reduce or completely nullify their efficacy. Hospitals are obligated to rigorously verify drug integrity before use and fully inform patients’ families of any associated risks. Local health authorities have launched an investigation, and the hospital involved has pledged full cooperation and internal process improvements. This case serves as a stark reminder: regardless of a drug’s cost, patient safety must always come first.
近日，一则关于‘3万多元一支的药剂疑似失效后仍被注射给患儿’的新闻引发社会广泛关注。据报道，某医院在治疗一名罕见病患儿过程中，使用了一支价格高达3万余元的特效药。然而，该药剂在运输或储存过程中可能因温度控制不当导致失效，但院方在未确认其有效性的情况下仍将其用于患儿治疗。事件曝光后，公众对高价药品的质量监管、医疗机构的操作规范以及患者知情权等问题提出强烈质疑。专家指出，此类高值药品通常对储存条件极为敏感，一旦超出规定温湿度范围，药效可能大幅降低甚至完全丧失。而医院在使用前应严格核查药品状态，并向患者家属充分说明风险。目前，当地卫健部门已介入调查，涉事医院也表示将配合核查并加强内部管理。此事件再次提醒医疗系统：无论药品价格高低，保障患者安全始终是第一要务。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/3129.html